• Jylamvo (Shorla)Expanded Formulation
    • To include the treatment of pediatric patients with acute lymphoblastic leukemia (ALL) and polyarticular juvenile idiopathic arthritis (pJIA).
  • Scemblix (Novartis)New Indication
    • For adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP).
  • Roxybond (Protega Pharmaceuticals)New Formulation
    • For the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
  • Orlynvah (Iterum Therapeutics)
    • For the treatment of uncomplicated urinary tract infections (uUTIs) caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women who have limited or no alternative oral antibacterial treatment options.
  • Abrysvo (Pfizer)Expanded Indication
    • For the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV.
  • Botox Cosmetic (Allergan Aesthetics)New Indication
    • For temporary improvement in the appearance of moderate to severe vertical bands connecting the jaw and neck (platysma bands) in adults.
  • Vyalev (AbbVie)
    • For 24-hour continuous subcutaneous infusion, for the treatment of motor fluctuations in adults with advanced Parkinson’s disease (PD).
  • Vyloy (Astellas)
    • In combination with fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma that is claudin 18.2 positive.
  • Lumryz (Avadel) Expanded Indication
    • For treatment of cataplexy or excessive daytime sleepiness in children 7 years of age and older with narcolepsy.
  • Selarsdi (Teva / Alvotech)Expanded Indication
    • As a biosimilar to Stelara, for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older.
  • Imuldosa (Accord BioPharma) Biosimilar to Stelara
    • For the treatment of chronic inflammatory conditions, including psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.
  • Hympavzi (Pfizer)
    • As routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients 12 years or older who have hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors.
  • Itovebi (Genentech)
    • For adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth-factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy.
  • Cologuard Plus (Exact Sciences)
    • Stool DNA test to screen adults 45 and older at average risk for colorectal cancer.
  • Opdivo (Bristol Myers Squibb) Expanded Indication
    • As neoadjuvant treatment, followed by single-agent nivolumab after surgery as adjuvant treatment, for adults with resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.

Sign up for alerts and stay informed on the latest published guidelines, FDA decisions, and more!

Copyright © 2024 Guideline Central, All Rights Reserved.